Advertise on podcast: Stem Cell Channel (Video)

Heart regeneration faces two connected challenges: replacing lost muscle and keeping transplanted cells safe and accepted by the body. Charles Murry, M.D., Ph.D., of USC explains why the adult heart heals major cardiomyocyte loss with scar tissue rather than new muscle, leading to progressive heart failure. Murry describes how stem cell derived cardiomyocytes can be manufactured at scale, transplanted into injured hearts, and tested for function in animal models. He also examines major barriers, including graft related arrhythmias, calcium handling stress, immune rejection, and the need for practical immunosuppression or immune edited cells. By connecting cell manufacturing, electrophysiology, immunology, and clinical trial planning, this research shows why heart regeneration is difficult and why careful translation matters for patients with severe heart injury. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40853]

Hematopoietic stem cells make blood across the lifespan, but they do not all behave the same way. Stephanie Xie, Ph.D., Scientist at Princess Margaret Cancer Centre, University of Toronto, examines how these rare cells self-renew, differentiate, and respond to inflammatory stress, asking whether differences in the stem cell pool help explain why aging affects people so differently. Xie identifies two hematopoietic stem cell subsets, including one that retains inflammatory memory after stress recovery, and connects this state to aging, clonal hematopoiesis, sickle cell disease, post-COVID recovery, and mortality risk markers in blood. Her research also raises questions about whether targeting the inflammatory environment, including through GLP-1 receptor agonists or metformin, could help mitigate clonal hematopoiesis. Understanding these patterns could clarify how inflammation shapes blood production, cancer risk, and immune health over time. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41406]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich’s ataxia, and Alzheimer’s research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter’s diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Pre-cancer and cancer can begin when stressed blood-forming stem cells lose their normal controls. Catriona Jamieson, M.D., Ph.D., UC San Diego, explains how inflammation-linked editing enzymes, repetitive elements in the genome, and stem cell stress shape the progression from myeloproliferative neoplasms to acute myeloid leukemia. Jamieson examines how spaceflight accelerates stem cell aging, how some astronauts mobilize a resilient regenerative stem cell population, and how tumor organoids in space help reveal drug responses by activating the enzyme ADAR1. This work helps explain how cancer starts, why it can return, and how space-based research may speed the development of therapies that stop malignant stem cells before disease advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41473]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic’s patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Microgravity can change biological systems in ways that may open new paths for biomedical research and commercialization in space. Twyman Clements, Space Tango, explains how “middleware” helps connect research use cases with space infrastructure by adapting terrestrial processes and supply chains for a spaceflight environment. Clements examines how long-duration microgravity creates different physical conditions, how Space Tango packages experiments into flight-ready lab systems, and how commercial space stations and reentry systems could help increase scale, throughput, and production value. He also points to more robotic systems that could support on-orbit sampling, imaging, and experiment assembly. This work helps explain how space-based biomedical research could move beyond small experimental missions and toward more practical, scalable platforms for discovery and development Series: "Stem Cell Channel" [Science] [Show ID: 41480]

Stem cell health in space matters for astronaut health and cancer research. Jessica Pham, UC San Diego, explains how spaceflight shapes normal hematopoietic stem cells and cancer stem cells through nano bioreactor studies, astronaut blood analysis, and tumor organoid work in low-Earth orbit. Pham examines increased cycling and reduced dormancy in space, reduced self-renewal after return, and ongoing research on cancer stem cells and their microenvironment, helping clarify how stem cells respond to spaceflight. This work helps explain how space conditions may change stem cell fitness over time and points toward a better understanding of astronaut health, long-duration missions, and cancer stem cell behavior. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41477]

Brain aging and neurological disease are hard to study because living human brain tissue is difficult to access. Alysson Muotri, Ph.D., UC San Diego, explains how brain organoids sent to space can model accelerated aging, reveal changes in neural networks, and help test potential treatments for brain disorders. Muotri examines space-induced senescence, fragmented network activity linked to dementia and Alzheimer’s patterns, and Rett syndrome findings showing inflammation tied to endogenous retroviruses and response to antiretroviral drugs in preclinical models. He also explores using brain organoids in space to screen neuroprotective compounds, including candidates identified from Amazon plants. This work helps explain how space biology can speed research on autism, Rett syndrome, Alzheimer’s disease, and other neurological conditions, and points toward new ways to test therapies on Earth. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41475]

Cognitive resilience depends on how the brain responds to environment, aging, and inflammation. J. Tiago Gonçalves, Ph.D., studies the hippocampus to examine how spatial memory is shaped by factors such as cognitive enrichment, exercise, social interaction, disease, and age. Gonçalves explains how adult neurogenesis and microglia help support the brain’s ability to encode information, and how disruptions in these systems can affect memory. He also shows that aging and systemic inflammation can weaken spatial encoding while still revealing signs of adaptation and recovery over time. By connecting brain plasticity, immune activity, and memory formation, Gonçalves presents a broader view of how cognition changes across the lifespan and how these mechanisms may inform future strategies for addressing cognitive decline Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40848]

Alpha Clinics in California accelerate the development of regenerative medicine therapies that use cells and genes to treat serious diseases. Patient advocate Tara Radcliffe Ghiglieri shares lived experience with gene therapy, while Sheldon Morris, M.D., M.P.H., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Catriona Jamieson, M.D., Ph.D., Michael Lewis, M.D., Mark Walters, M.D., and Leo D. Wang, M.D., Ph.D., describe how Alpha Clinic teams design and deliver clinical trials for a wide range of conditions, including cancer, blood disorders, neurologic disease, osteoarthritis, metabolic disorders, pulmonary arterial hypertension, and Duchenne muscular dystrophy. They highlight how coordinated networks, community partnerships, and genomic tools help expand access, lower financial barriers, and bring promising cell and gene therapies to more patients while carefully tracking safety, effectiveness, and long-term outcomes. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41168]

Off-the-shelf immune cell therapies using engineered T cells represent an important direction in cancer treatment. Lili Yang, Ph.D., at UCLA develops an off-the-shelf platform based on invariant natural killer T (iNKT) cells generated from hematopoietic stem cells, often sourced from cord blood. Yang programs these stem cells with iNKT cell receptors, chimeric antigen receptors (CARs), and genes such as IL-15 to create pure, expandable iNKT products that recognize lipid antigens presented by non polymorphic CD1d molecules. These cells combine multiple killing mechanisms, infiltrate tissues, target tumor cells and immunosuppressive myeloid cells, and show reduced risk of graft versus host disease and cytokine release syndrome in preclinical models. Yang’s group tests this strategy in models of blood cancers and solid tumors, aiming to generate many therapeutic doses from a single donor. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 40846]

RNA binding proteins help cells control how genetic information becomes working proteins, and Gene Yeo, Ph.D., M.B.A., at UC San Diego investigates how their disruption contributes to neurodegenerative disease. Yeo focuses on ALS, a severe motor neuron disease in which the RNA binding protein TDP-43 moves from the nucleus to the cytoplasm, loses normal RNA processing functions, and triggers cryptic exons that damage key neuronal genes, including one linked to motor neuropathy. His group maps these RNA changes and develops small nuclear RNA guides packaged in AAV vectors to block harmful splice sites and restore healthy RNA and protein levels. In cell cultures and a humanized mouse model, this strategy improves axon growth and supports the idea that multiplexed RNA-targeted therapies could correct multiple disease pathways at once. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41166]

Aging is the leading risk factor for cancer, Alzheimer’s, diabetes, and heart disease, and Robert A.J. Signer, Ph.D., studies how aging stem cells shape pre-cancer and healthspan. As deputy director of the Sanford Stem Cell Discovery Center, Signer focuses on rare blood-forming stem cells that self-renew, generate all blood and immune cells, and normally sustain more than 35 trillion blood cells, including about 2 million new red blood cells every second. His group finds that these “Zen” stem cells slow protein production to limit damaging “trash,” but aging stresses overwhelm these defenses. Stress response programs such as HSF1 then help both healthy and mutant stem cells, fueling clonal hematopoiesis, a common, untreated pre-cancerous condition linked to cardiovascular disease, inflammation, cancer, and increased mortality. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41253]

Stem cell science is reshaping treatment for complex disorders of the brain and spinal cord. Researchers develop cell based therapies to replace lost dopaminergic neurons in Parkinson’s disease, fill gaps across spinal cord injuries, and calm seizure networks in refractory epilepsy by restoring the balance of inhibition and excitation. Teams test immune cell therapies against Epstein Barr virus infected B cells in multiple sclerosis and collaborate to move treatments across the blood brain barrier to reach diseased cells. Clinicians combine imaging in the operating room, surgical tools, and research on biological age and the pace of aging to understand disease and guide treatment. Patient advocates describe challenges and hopes for better options, and contemporary art reflects on perception in digital and physical worlds. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40992]